December 2007

Rapid correction of hyperglycemia in a diabetic patient with coronary stenosis

November 05, 2008

Lipids

A 62-year-old man presented with a 3-day history of intermittent episodes of central chest discomfort and associated dyspnea, culminating in a 20-minute episode occurring at rest, with marked diaphoresis and associated anguor animi.

Prognostic value of multislice computed tomography coronary angiography

September 08, 2008

Lipids

We evaluated 100 subjects who underwent multislice computed tomography (MSCT) to assess the presence and severity of coronary artery disease (CAD) and to determine the occurrence of coronary events (including cardiac death, nonfatal myocardial infarction, unstable angina requiring hospitalization, and revascularization) over a follow-up period of 16 months.

Prediction of coronary artery disease in patients with diabetes and albuminuria

September 08, 2008

Lipids

We developed a set of equations to predict the risk or probability of developing coronary artery disease (CAD) in 10 years among American Indians. The equations are based on the significant risk factors identified in the Strong Heart Study, a longitudinal study of cardiovascular disease in American Indians. The equations can be used in patient education and to evaluate the efficacy of CAD prevention and intervention programs.

Hyperglycemia and platelet function in diabetic patients: Relevance to acute myocardial ischemia and infarction

September 08, 2008

Lipids

Diabetic patients with acute coronary syndromes are at higher risk for mortality, even if they have ST-segment elevation myocardial infarction. Diabetic patients with unstable angina/non–Q-wave infarction have impaired platelet responsiveness to nitric oxide, a physiological anti-aggregating autocoid. The extent of this impairment depends on the degree of hyperglycemia. Rapid correction of hyperglycemia with infused insulin restores responsiveness to nitric oxide, thus ameliorating platelet dysfunction.

Obesity-related hypertension

September 08, 2008

Lipids

To evaluate the interactions between the weight loss drug, sibutramine, and different antihypertensive treatments, we randomly assigned 171 subjects taking 3 antihypertensive treatment regimens to receive sibutramine or placebo. Our study showed for the first time that combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker is more advantageous than a ß blocker/diuretic-based-regimen with regard to supporting the weight-reducing actions and metabolic changes induced by sibutramine.